EDP Biotech Corporation has developed an immunodiagnostic test for colorectal cancer called CA1-18 Enzyme Immunoassay (EIA).

The CA1-18 test is a monoclonal-polyclonal sandwich EIA for the quantitative measurement of CA1-18 (Tennessee Antigen) in human serum. Tennessee Antigen, a tumor-associated antigen, is present in elevated levels in the serum of patients with various carcinomas, particularly colorectal cancer.

The diagnostic test is now available to research customers, and DP plans to submit the CA1-18 EIA to the U.S. Food and Drug Administration (FDA) for marketing clearance in April 2007.

Source: MarketWire

[Image: See larger version from EDP Biotech]